The global irritable bowel syndrome treatment market size is expected to reach USD 6.02 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.
IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient’s professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.
Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient’s professional and personal activities, and usually limits an individual’s potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.
Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.
This product will be delivered within 1-3 business days.
IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient’s professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.
Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient’s professional and personal activities, and usually limits an individual’s potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.
Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.
Irritable Bowel Syndrome Treatment Market Report Highlights
- The IBS-C segment is expected to grow at a CAGR of 11.9% over the forecast period, owing to the increasing prevalence of this condition and the rising adoption of effective medications such as Linzess (linaclotide) and Amitiza (lubiprostone).
- The IBS-D segment dominated the market with the largest revenue share of 49.8% in 2024 attributed to a rise in diagnosed cases and an increasing understanding of the condition's impact on quality of life.
- Linzess/Constella dominated the market and accounted for the largest revenue share of 37.3% in 2024 attributed to its effectiveness in managing constipation-predominant IBS (IBS-C).
- Hospital pharmacies led the market and accounted for the largest revenue share in 2024, which is attributed to their comprehensive infrastructure and integrated patient care systems.
- North America irritable bowel syndrome (IBS) treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to the high prevalence of IBS and the increasing awareness of its management options.
- The growth of Europe irritable bowel syndrome treatment market is driven by increasing awareness campaigns aimed at destigmatizing gastrointestinal disorders. Countries such as Germany and the UK are seeing increased patient engagement regarding IBS symptoms and available treatments.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
- Competitive Landscape: Explore the market presence of key players worldwide
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
The leading players in the Irritable Bowel Syndrome Treatment market include:
- Ironwood Pharmaceuticals, Inc.
- Allergan
- Astellas Pharma, Inc.
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Sanofi S.A.
- Sebela Pharmaceuticals Inc.
- Bausch Health
- Synthetic Biologics, Inc.
- Ardelyx
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Irritable Bowel Syndrome Treatment Market Variables, Trends, & Scope
Chapter 4. Irritable Bowel Syndrome Treatment Market: Type Estimates & Trend Analysis
Chapter 5. Irritable Bowel Syndrome Treatment Market: Drug Class Estimates & Trend Analysis
Chapter 6. Irritable Bowel Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Irritable Bowel Syndrome Treatment Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Ironwood Pharmaceuticals, Inc.
- Allergan
- Astellas Pharma, Inc.
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Sanofi S.A.
- Sebela Pharmaceuticals Inc.
- Bausch Health
- Synthetic Biologics, Inc.
- Ardelyx
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 100 |
Published | October 2024 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 3.64 Billion |
Forecasted Market Value ( USD | $ 6.02 Billion |
Compound Annual Growth Rate | 8.8% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |